FDA hits Leo Pharma with a CRL for what the biotech says are questions about the 'device component' of eczema candidate

After toiling away for the last few years on a monoclonal antibody to compete with Dupixent in atopic dermatitis, Leo Pharma has been hit with a complete response letter from the FDA.